Schott Pharma AG KGaA (WBO:1SXP) EPS (Basic): €0.95 (TTM As of Mar. 2026)


WBO:1SXP Schott Pharma AG & CO KGaA WBO:1SXP
61 GF Score
Price €16.80
GF Value €28.05
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA EPS (Basic)?

Schott Pharma AG KGaA WBO:1SXP -1.75% 61 EPS (Basic) is €0.95 as of Mar. 2026. GuruFocus rates WBO:1SXP with a GF Score™ of 61/100 and a GF Value™ of €28.05 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Schott Pharma AG KGaA's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.21. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.95.

Schott Pharma AG KGaA's EPS (Diluted) for the three months ended in Mar. 2026 was €0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.95.

Schott Pharma AG KGaA's EPS without NRI for the three months ended in Mar. 2026 was €0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.95.

During the past 12 months, Schott Pharma AG KGaA's average EPS without NRIGrowth Rate was -3.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 3.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Schott Pharma AG KGaA's highest 3-Year average EPS without NRI Growth Rate was 25.10% per year. The lowest was 3.20% per year. And the median was 14.20% per year.

Schott Pharma AG KGaA  (WBO:1SXP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Schott Pharma AG KGaA EPS (Basic) Related Terms

Schott Pharma AG KGaA EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA EPS (Basic) Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial 0.67 0.83 1.01 0.99 0.97

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.30 0.22 0.22 0.21
WBO:1SXP
61GF Score
Schott Pharma AG & CO KGaA WBO:1SXP
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Schott Pharma AG KGaA's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(146.454-0)/150.615
=0.97

Schott Pharma AG KGaA's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(31.013-0)/147.681
=0.21

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.95 mean?
Schott Pharma AG KGaA (WBO:1SXP) has a EPS (Basic) of €0.95 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Schott Pharma AG KGaA and its competitors.
Is Schott Pharma AG KGaA's EPS (Basic) too high?
Schott Pharma AG KGaA's current EPS (Basic) is €0.95. Overall, Schott Pharma AG KGaA has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's EPS (Basic) compare to ISRG and BDX?
Schott Pharma AG KGaA's EPS (Basic) of €0.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Schott Pharma AG KGaA and its competitors. Schott Pharma AG KGaA's current EPS (Basic) is €0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (WBO:1SXP) is currently considered Significantly Undervalued. The stock's GF Value™ is €28.05, compared to a current price of €16.80 — trading 40.1% below its estimated fair value. The current EPS (Basic) is €0.95. Schott Pharma AG KGaA's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Schott Pharma AG KGaA (WBO:1SXP), the current EPS (Basic) is €0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (WBO:1SXP) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of €16.80 is trading 40.1% below its estimated GF Value™ of €28.05. GuruFocus considers Schott Pharma AG KGaA to be Significantly Undervalued.

Key valuation signals for WBO:1SXP:

  • EPS (Basic): €0.95
  • GF Value™: €28.05 vs. price of €16.80 (40.1% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the WBO:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Other Exchanges 1SXP:Italy1SXP:Germany
Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
61GF Score

Get the complete analysis for WBO:1SXP

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.80
Price
€28.05
GF Value